Home - Products - Others - Other Targets - Amabiloside

Amabiloside

CAS No. 40555-38-2

Amabiloside( ——— )

Catalog No. M38347 CAS No. 40555-38-2

Amabiloside is a glycoside that can be isolated from Crinum amabile.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
25MG	Get Quote	Get Quote
50MG	Get Quote	Get Quote
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Amabiloside
Note

Research use only, not for human use.
Brief Description

Amabiloside is a glycoside that can be isolated from Crinum amabile.
Description

Amabiloside is a glycoside that can be isolated from Crinum amabile.
In Vitro

———
In Vivo

———
Synonyms

———
Pathway

Others
Target

Other Targets
Recptor

———
Research Area

———
Indication

———

Chemical Information

CAS Number

40555-38-2
Formula Weight

300.26
Molecular Formula

C13H16O8
Purity

>98% (HPLC)
Solubility

———
SMILES

———
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Likhitwitayawuid K, et al. Amabiloside, a new glycoside from Crinum amabile. Natural Product Letters, 1993, 3(1): 1-4.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Terflavoxate

Terflavoxate is a novel, orally active, semisynthetic statin microtubule inhibitor commonly used in combination with capecitabine. Terflavoxate is used in cancer research.
(D-2-Nal5,Cys6·11,Ty...

BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?, ICI 216140 and DPDM-bombesin ethylamide-induced Ca2+ release.
LY-3475070

LY-3475070 is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.

Sign In Join Free